FDA approves Darzalex® (daratumumab) as a treatment for myeloma

Genmab, the Danish biotechnology company, and its collaborative partner, Janssen Biotech Inc., have announced that the US Food and Drug Administration (FDA) has approved the use of daratumumab as a treatment for relapsed and/or refractory myeloma patients who have received at least three previous lines of treatment including a proteasome inhibitor (PI) and an immunomodulatory…

Details